Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB

Condition(s) studied

Investigational drug(s) / intervention(s)

ceftazidime-avibactam combined with aztreonam: Ceftazidime-avibactam 2.5g every 8 hours (q8h) administered as a 3-hour concomitant intravenous infusion with aztreonam 2g q8h, versus ceftazidime-avibactam 2.5g q8h infused over 2 hours followed by a 1-hour intravenous infusion of aztreonam

Study summary

Metallo-β-lactamase-producing carbapenem-resistant Gram-negative bacteria (MBL-CR-GNB), due to their capacity to hydrolyze almost all β-lactam antibiotics, have become a critical global threat in antimicrobial resistance. Current novel β-lactamase inhibitors (e.g., avibactam, relebactam, vaborbactam) only inhibit serine enzymes and are ineffective against metallo-β-lactamases (MBL), severely limiting clinical treatment options. Aztreonam (ATM) is inherently stable against MBL, while avibactam (AVI) inhibits co-produced serine β-lactamases (e.g., KPC, OXA-48). Their combination achieves complementary synergistic antibacterial effects. The ceftazidime-avibactam plus aztreonam (CZA+ATM) regimen, operating via the mechanism of "avibactam protecting aztreonam", has demonstrated synergistic bactericidal activity against NDM, VIM, IMP and other MBL-producers in multiple real-world and clinical studies, significantly reducing infection-related mortality.However, although current domestic and international guidelines recommend the CZA+ATM combination for MBL infections, there is no consensus on optimal infusion strategies. Based on the above, this study hypothesizes that in patients with complicated infections caused by MBL-producing CR-GNB, different infusion modalities of ceftazidime-avibactam combined with aztreonam-concomitant infusion versus sequential infusion-will show no significant differences in PK/PD target attainment rates, clinical cure rates, microbiological eradication rates, or all-cause mortality, without increasing the risk of adverse events.

Eligibility

Primary outcome measure(s)

• Clinical cure rate — 14 days
  Clinical cure at Day 14 of treatment

Trial sites (1)